The positive data supports a regulatory submission for US label expansion. Traders should monitor for FDA submission timing in H2 2026 and subsequent approval decision. Given the small patient population for IOPD, the financial impact is likely limited for a $105B market cap company, but the news reinforces the drug's clinical profile and may support modest upside.
Drug in focus
SNY drug pipeline →Nexviazyme
● Neutral Named in this 6-K- Impact
- Phase
- Approved
- Time to market
- Already on the market since August 2021 (US) for late-onset Pompe disease. Label expansion to infantile-onset Pompe could come in 2027 pending FDA submission and review.
- Next catalyst
- None dated
What to watchThe Baby-COMET Phase 3 topline readout (June 30, 2026) was a positive milestone already priced in. Watch for the formal FDA submission in H2 2026 and the eventual PDUFA decision, likely a 2027 event, which could add ~€100-200M in peak sales from the infantile-onset population. The bigger competitive overhang is BioMarin's newly acquired Pombiliti+Opfolda combo, which Danish regulators found equally effective and which may pressure Sanofi's Pompe franchise pricing.
- ◆ venglustat 5/10 Filed/PDUFA for Gaucher type 3 (NDA under FDA priority review); Phase 3 ongoing in Fabry disease; Phase 3 GM2 (Tay-Sachs
- ● Qfitlia 4/10 Approved
- ● Alprolix 3/10 Approved
- ● ALTUVIIIO 3/10 Approved (US)
- ● Anxu 3/10 Approved in China (NMPA); Phase III ongoing for cGVHD
- 16 more · All SNY drugs, catalysts & trials →
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $42.98entry
- T+1 · 4mo ago −0.47%α −0.16% · $42.78
- T+5 · 4mo ago +0.47%α −0.09% · $43.18
- T+20 · 4mo ago −0.07%α −1.40% · $42.95
- T+60 · 7w ago −4.07%α −6.07% · $41.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Sanofi reported positive phase 3 results for Nexviazyme (avalglucosidase alfa) in infantile-onset Pompe disease (IOPD). The Baby-COMET study met all primary and secondary endpoints, including the primary endpoint of participants alive and free of invasive ventilation at 52 weeks. Sanofi intends to file for a US label extension in H2 2026, which could modestly expand the drug's addressable market. The safety profile was consistent with the established profile.
Key Facts
- Nexviazyme met its primary endpoint in the Baby-COMET phase 3 study: proportion of participants alive and free of invasive ventilation at 52 weeks.
- All secondary endpoints were met, including proportion alive and free of invasive ventilation at 12 and 18 months of age.
- Sanofi plans to submit the data for a US label extension in the second half of 2026.
- No serious treatment-related adverse events, deaths, or discontinuations were reported.
- Nexviazyme is already approved in the US for late-onset Pompe disease (2021) and in Europe for both LOPD and IOPD (2022).
Financial Impact
Modest incremental revenue potential from label expansion to include infantile-onset Pompe disease, a very rare condition. No specific financial figures were provided in the filing.
Risk Factors
- Regulatory approval for the IOPD label extension is not guaranteed and may face delays.
- The single-arm, open-label study design may limit the strength of the evidence.
- Small patient population limits revenue potential; competition from enzyme replacement therapies exists.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-296990 |
| Document: d102781d6k.htm | 0001193125-26-296990 |
| Document: 0001193125-26-296990-index-headers.html | 0001193125-26-296990 |
| Document: 0001193125-26-296990-index.html | 0001193125-26-296990 |
| Document: 0001193125-26-296990.txt | 0001193125-26-296990 |
Track record
15 reports on SNY
4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +7.69% at T+60 after the Aug 17, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $47.47 to $48.43 Now $48.39 +1.94% ▲ +2.02% +2.94% vs SPY
- Oct 30, 202617d ago 6-K Bullish 6/10 Entry $44.34 to $47.04 Now $48.39 +9.13% ▲ +6.09% +8.79% vs SPY
- Oct 26, 202621d ago SC 13G/A Neutral 2/10 Entry $41.89 to $45.33 Now $48.39 +15.52% ▲ +8.21% +10.20% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $41.79 to $44.34 Now $48.39 +15.79% ▲ +6.10% +7.36% vs SPY
- Oct 1, 20266w ago 6-K Mixed 5/10 Entry $40.67 to $40.23 Now $48.39 +18.98% ▼ −1.08% −2.38% vs SPY
- Sep 17, 20268w ago 6-K Neutral 4/10 Entry $43.14 to $40.94 Now $48.39 +12.17% ▼ −5.10% −5.95% vs SPY
- Aug 31, 202611w ago Court Ruling Neutral 2/10 Entry $44.37 to $42.85 Now $48.39 +9.06% ▼ −3.43% −3.51% vs SPY
- Aug 17, 202613w ago Court Ruling Bullish 4/10 Entry $44.97 to $46.02 Now $48.39 +7.61% ▲ +2.33% +2.54% vs SPY
- Aug 12, 202613w ago Court Ruling Neutral 2/10 Entry $43.78 to $45.15 Now $48.39 +10.53% ▲ +3.13% +5.09% vs SPY
- Jul 31, 202615w ago Court Ruling Bullish 5/10 Entry $42.95 to $43.48 Now $48.39 +12.67% ▲ +1.23% −0.79% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers